Arca
Skip to content
Tools
Tools

SCN10A: Sodium channel protein type 10 subunit alpha

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Tetrodotoxin-resistant channel that mediates the voltage- dependent sodium ion permeability of excitable membranes.

  • Drugs that act on it: 4
  • Approved: 1
  • In phases 1 to 3: 3
  • Sponsors: 3

Who Is On It, and How Far Along

Every drug ChEMBL records acting on SCN10A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved1

  • Dibucaine

Phase 30

    Phase 22

    • Afacifenacin
    • PF-04531083

    Phase 11

    • DSP-2230

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    Modalities

    Drugs on this target by ChEMBL molecule type.

    • Small molecule4100%

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Sodium channel protein type X alpha subunit blocker.
    DibucaineApprovedNovartis PharmaceuticalsSmall moleculeBlocker—0—
    AfacifenacinPhase 2Sumitomo PharmaSmall moleculeBlocker—0—
    PF-04531083Phase 2PfizerSmall moleculeBlocker—0—
    DSP-2230Phase 1—Small moleculeBlocker—0—

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Episodic pain syndrome, familial, 2
    0.72
    Cardiac arrhythmia
    0.68
    Sodium channelopathy-related small fiber neuropathy
    0.63
    Pain
    0.61
    Seizure
    0.60

    Genes and Related Targets

    Complexes and families that share a gene with this target
    Genes
    SCN10A

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5451, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q9Y5Y9, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.